SCHEMBL283909

SCHEMBL283909

CS(=O)(=O)c1cccc(Nc2nc(NC3CCC(O)CC3)cnc2C(N)=O)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALK Q9UM73 5/20 0.70
EML4 Q9HC35 4/20 0.70
LCK P06239 3/20 0.54
JAK3 P52333 3/20 0.54
ROCK1 Q13464 2/20 0.54
BTK Q06187 2/20 0.54
ITK Q08881 2/20 0.54
TYRO3 Q06418 2/20 0.54
CDC7 O00311 1/20 0.54
PLK4 O00444 1/20 0.54
CHEK1 O14757 1/20 0.54
PDPK1 O15530 1/20 0.54
DAPK3 O43293 1/20 0.54
DYRK3 O43781 1/20 0.54
JAK2 O60674 1/20 0.54
ROCK2 O75116 1/20 0.54
RPS6KA5 O75582 1/20 0.54
PRKD3 O94806 1/20 0.54
MAP4K4 O95819 1/20 0.54
PAK4 O96013 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL283908 1.00 ALK (0.70) ALKEML4LCKJAK3ROCK1
SCHEMBL10129129 0.90 ALK (0.58) ALKEML4LCKJAK3ROCK1
SCHEMBL10128635 0.84 ALK (0.80) ALKEML4RETROS1SYK
SCHEMBL282450 0.84 ALK (0.80) ALKEML4RETROS1SYK
SCHEMBL282449 0.84 ALK (0.80) ALKEML4RETROS1SYK
SCHEMBL14955386 0.84 ALK (0.77) ALKEML4LCKJAK3ROCK1
SCHEMBL16305339 0.84 ALK (0.50) ALKEML4LCKJAK3ROCK1
SCHEMBL282302 0.83 ALK (0.79) ALKEML4RETROS1SYK
SCHEMBL283392 0.83 ALK (0.79) ALKEML4RETROS1SYK
SCHEMBL282303 0.83 ALK (0.79) ALKEML4RETROS1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 EP disclosed
EP-2428508-B9 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2016-04-20 EP disclosed
EP-2428508-B1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC (JP) 2015-12-16 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
EP-2428508-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2012-03-14 EP disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALK 2/4885EML4 1/4885LCK 353/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 ALK 2/4885EML4 1/4885LCK 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.